In a significant recognition of its advancements in generative AI (GenAI) adoption, Indegene has been acknowledged as a front-runner by Everest Group, a leading global research and consulting firm. The acknowledgment comes through Everest Group’s latest report, ‘AI-deas to Action: Operationalizing Generative AI in Life Sciences’, which highlights Indegene’s enterprise-wide capabilities in GenAI, its broad spectrum of use cases, and its strategic partnerships that drive tangible value for clients.

The report underscores how Indegene’s holistic GenAI strategy, coupled with its enterprise-grade, production-ready solutions, is enabling life sciences companies to streamline operations and achieve significant productivity gains. These efficiencies span various stages of the life sciences value chain, including clinical research, medical functions, and commercial operations.

“We believe GenAI is a generational opportunity for life sciences leaders to make the strategic leap and drive transformational business impact. And we are helping them make the most of GenAI’s potential – solve real business challenges, prioritize use cases that deliver clear business outcomes, and realize benefits in a responsible and compliant way,” said Tarun Mathur, CTO, Indegene. “This recognition by the Everest Group reinforces our commitment to contextualizing GenAI for some of the most challenging use cases, and help leaders tackle them with fit-for-purpose solutions.”

Also Read :- Nivaan Care Secures $4.25M in Seed Funding to Transform Chronic Pain Management in India

Everest Group’s assessment framework for service providers’ GenAI capabilities is based on four key parameters: scale, measured through revenue, client reach, and pipeline; the impact of industry-specific use cases across the life sciences value chain, whether in pilot or production stages; the breadth and effectiveness of strategic partnerships; and the measurable value delivered to clients.

Indegene’s deep-rooted healthcare expertise, combined with its digital-first approach, has made it a trusted partner for pharmaceutical, biotech, and medical device companies looking to commercialize their products effectively. Serving an extensive clientele, including the world’s top 20 biopharma companies as well as numerous emerging biotech firms and medical device manufacturers, Indegene has established itself as a global leader. With over 5,000 employees across six operation hubs and 18 offices spanning North America, Europe, and Asia, the company continues to drive innovation at scale.

This recognition further solidifies Indegene’s position as a transformative force in the life sciences industry, demonstrating its ability to harness GenAI’s potential to drive efficiency, compliance, and strategic growth in the sector.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!